![]() |
市场调查报告书
商品编码
1800841
2025 年至 2033 年基因组学市场报告(按组件、应用、技术、最终用户和地区划分)Genomics Market Report by Component, Application, Technology, End-User, and Region 2025-2033 |
2024 年全球基因体学市场规模达 384 亿美元。展望未来, IMARC Group预计到 2033 年市场规模将达到 1,133 亿美元,2025-2033 年期间的复合年增长率 (CAGR) 为 12.77%。市场的主要成长动力是新一代定序 (NGS) 在癌症等慢性疾病中越来越多地用于检测基因异常,以及需要基因组定序的遗传和病毒性疾病的盛行率上升。此外,基因组学领域尖端技术的引入正在增强应用和研究。再者,个人化医疗的使用日益增多,推动了对基于基因组资讯的客製化治疗方案的需求,从而改善了患者的治疗效果。
定序技术的技术创新
根据基因组学市场分析,创新技术的快速进步,尤其是新一代定序 (NGS) 和 CRISPR-Cas9 基因组改造创新,是基因组学市场的重要驱动力。新兴新创公司为诊断、个人化医疗和研究等多种用途提供定序服务。 NGS 等先进技术极大地改进了基因组分析,使其更快、更精确、更经济。政府和产业资金对于市场成长、支持研究工作和创新技术商业化也至关重要。例如,23andMe(一家在消费者基因检测领域占据领先地位的公司)和 Genome Medical(最近获得 1400 万美元资金以增强其远距医疗基因咨询服务)等例子,凸显了基因组学与医疗服务日益融合的趋势。这些进步有助于使基因组学更易于获取和使用,从而使 2025 年全球基因组学市场规模实现显着增长。
个人化医疗需求不断成长
推动市场发展的另一个重要驱动力是全球对个人化医疗日益增长的需求,个人化医疗是指根据每位患者的独特特征量身定制医疗方案。个人化医疗在很大程度上依赖基因资料,以便根据个人基因组成製定特定的疗法,从而摆脱传统医学的泛泛之谈,转向更精准、更有效的治疗方案。这也有助于提高消费者的认知度,帮助他们找到「基因组学市场是什么?」这个问题的答案。此外,人们对疾病遗传病因的认识和了解不断加深、遗传性疾病的发生率不断上升,以及传统疗法对各种疾病的局限性,也推动了需求的不断增长。在个人化医疗中运用基因组学旨在透过优先预防和精准治疗来改善患者的治疗效果,并提供经济高效的医疗保健方案,从而推动基因组学领域的更多投资和研究。
临床应用和诊断的扩展
基因组学技术在临床应用和诊断领域的应用日益广泛,例如识别遗传疾病、癌症筛检和监测传染病,也推动了市场的成长。对疾病遗传基础的深入了解使得基因组学能够融入临床护理,从而催生出新的诊断工具和基因检测,用于预测个体患特定疾病的风险、指导治疗选择并追踪疾病进展。不禁要问:基因体学的需求究竟有多大,尤其是在临床应用与诊断领域?基因组学技术的进步预计将继续推动该领域的需求,拓展其在液体活检和非侵入性产前检测 (NIPT) 等诊断领域的潜力,凸显基因组学在医疗保健和诊断领域革新中的关键作用。
耗材和试剂占据大部分市场份额
耗材和试剂产业因其在DNA定序、基因编辑和样品製备等各种基因组学程序中发挥的重要作用而占据市场主导地位。随着基因组学在医疗保健、农业和生物技术等领域的应用日益广泛,对特定耗材和试剂的需求也日益增长,促使製造商不断增强和扩展其产品范围。这促进了耗材产业的发展,凸显了其在推动和应用基因组学技术方面的关键作用,为市场的整体成长做出了重大贡献。此外,这些产品对于确保研究和临床诊断中基因组分析的准确性和可靠性至关重要,市场对这些产品的强劲需求进一步巩固了该行业的主导地位。
功能基因组学占据行业最大份额
功能基因组学专注于研究基因功能和相互作用,已成为市场主导领域,展现了其在理解复杂生物过程和疾病机制方面的关键作用。功能基因组学利用RNA定序和CRISPR-Cas9等高通量技术,能够深入研究基因表现和调控,进而推动生物医学研究和医疗保健领域的进步。此外,随着技术快速进步,人们对探索基因组功能特征的日益重视,使功能基因组学成为推动整个市场成长和创新的主要力量。
测序代表着领先的细分市场
定序技术是市场的主要组成部分,因为它在解读DNA和RNA中的遗传讯息方面发挥着至关重要的作用,使其成为最大的技术领域。定序技术能够揭示遗传变异和突变,从而提供关键洞见,推动其在个人化医疗、遗传研究和诊断应用领域中占据重要地位。此外,新一代定序(NGS)技术的兴起也正在改变这一领域,它比传统技术拥有更快的速度、更高的准确性和更高的成本效益。新一代定序技术能够对基因组、外显子组和转录组进行详细分析,进而推动对复杂疾病、演化生物学和微生物基因体学的理解。
製药和生物技术公司在市场上占据明显主导地位
製药和生技公司在市场中扮演着重要角色,强调其在推动药物开发和个人化医疗方面的重要性。这些领域应用基因组资料来确定药物的新标靶,了解疾病的遗传起源,并利用个人基因资料开发客製化治疗方案。例如,全球 DNA 定序和阵列技术的顶尖公司 Illumina Inc. 与范德堡大学医学中心 (VUMC) 旗下着名的临床和基因组资料公司 Nashville Biosciences, LLC 合作,揭晓了基因组发现联盟 (AGD) 的五个创始成员。该扩展协议旨在透过进行彻底的基因组学研究和建立高品质的临床基因组学资料库来加快治疗开发过程。 AbbVie、Amgen、AstraZeneca、Bayer 和 Merck 将集中资源资助 250,000 个样本的定序,并可使用这些资料来开发药物和改进疗法。
北美引领市场,占据基因组学最大市场份额
该报告还对所有主要区域市场进行了全面分析,包括北美(美国和加拿大);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告指出,北美是基因组学最大的区域市场。
北美凭藉其先进的医疗保健体系、雄厚的研发投入以及顶尖製药和生物技术公司的聚集,占据了最大的市场份额。此外,该地区在基因组学和生物资讯学领域的先进技术,以及这些因素,为基因组学领域的发展和进步创造了良好的环境。北美在全球市场的强势地位得益于学术和研究机构与产业界的密切合作,这促进了创新,并引领了影响全球基因组学实践和政策的趋势。
市场研究报告还对市场竞争格局进行了全面分析,并提供了所有主要公司的详细资料。基因组学行业的一些主要市场参与者包括
产业主要参与者正积极进行各种策略活动,以维护和巩固其市场地位。这些企业正在大力投资研发,以推出新的基因组技术、服务和解决方案,以满足客户不断变化的需求。合作、建立伙伴关係和进行收购是重要的策略,有助于他们提昇技术能力、进入新市场并获得新的基因组应用和智慧财产权。此外,这些顶尖公司正致力于改进其生物资讯系统,以管理和分析基因组定序产生的大量资料。这将有助于提供完整的解决方案,将基因组学发现转化为临床和农业领域的进步。
The global genomics market size reached USD 38.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 113.3 Billion by 2033, exhibiting a growth rate (CAGR) of 12.77% during 2025-2033. The market's main growth drivers are the increasing use of next-generation sequencing (NGS) in chronic diseases like cancer to detect genetic abnormalities and the rise in the prevalence of hereditary and viral disorders that require genomic sequencing. Additionally, the introduction of cutting-edge technologies in the genomics sector is enhancing applications and research. Furthermore, patient outcomes are being improved by the growing use of personalized medicine, which is driving the need for customized treatment regimens based on genomic information.
Technological innovations in sequencing technologies
According to the genomics market analysis, the fast pace of innovative advancements, especially in next-generation sequencing (NGS) and CRISPR-Cas9 genome altering innovations, serves as an essential driver for the genomics showcase. The emergence of startups providing sequencing services for diverse uses, such as diagnostics, personalized medicine, and research. Sophisticated technologies like NGS have greatly improved genomic analysis, ensuring it is quicker, more precise, and economical. Government and industry funding are also vital in growing the market, aiding research efforts and the commercialization of innovative technologies. Examples like 23andMe, a prominent player in consumer genetic testing, and Genome Medical, which recently obtained $14 million in funding to enhance its telehealth genetic consultations, underscore the growing fusion of genomics and healthcare services. These advancements contribute to making genomics more attainable and usable, thereby making the global genomics market size 2025 experience significant growth.
Growing demand for personalized medicine
Another important driver of the market is the rising across the globe need for personalized medicine, which customizes medical care according to each patient's unique characteristics. Customized medical treatment depends greatly on genetic data to inform the creation of specific therapies tailored to an individual's genetic composition, moving away from the generalized approach of traditional medicine to more accurate and efficient treatments. This also facilitates enhanced awareness among consumers that helps them find an answer for the "what is the genomics market?" question. Along with this, the increasing need is fueled by the expanding recognition and knowledge of the genetic causes of diseases, the increasing frequency of genetic conditions, and the limitations of conventional therapies for various illnesses. Using genomics in personalized medicine aims to enhance patient results and provides a cost-effective healthcare approach by prioritizing prevention and accurate treatment, which drives more investments and research in genomics.
Expansion in clinical applications and diagnostics
The market is also growing due to genomics technologies being utilized more for clinical applications and diagnostics, such as identifying genetic disorders, cancer screening, and monitoring infectious diseases. Improved understanding of the genetic basis of diseases has allowed for the incorporation of genomics into clinical care, resulting in the creation of novel diagnostic tools and genetic tests that can anticipate an individual's risk for specific conditions, guide treatment choices, and track disease advancement. A question arises, what is the demand for genomics, particularly in the field of clinical applications and diagnostics? Advancements in genomics technologies are anticipated to keep driving demand in this field, expanding their potential in diagnostics such as liquid biopsies and NIPT, highlighting the critical role genomics plays in revolutionizing healthcare and diagnostics.
Consumables and reagents account for the majority of the market share
The consumables and reagents sector dominates the market due to their essential role in a variety of genomic procedures including DNA sequencing, gene editing, and sample preparation. With the increased use of genomics in sectors such as healthcare, agriculture, and biotechnology, there is a rising need for specific consumables and reagents, leading manufacturers to enhance and extend their product range. This is promoting the development of the consumables industry, emphasizing its crucial role in driving and applying genomics technologies, making a substantial contribution to the market's overall growth. Moreover, the strong demand for these products, which are essential for ensuring the accuracy and reliability of genomic analyses in research and clinical diagnostics, further solidifies the dominance of this industry sector.
Functional genomics holds the largest share of the industry
Functional genomics, which focuses on gene functions and interactions, has become the dominant area in the market, showcasing its crucial importance in comprehending intricate biological processes and disease mechanisms. Utilizing high-throughput technologies including RNA sequencing and CRISPR-Cas9 in functional genomics enables in-depth study of gene expression and regulation, leading to progress in biomedical research and healthcare. Moreover, the growing emphasis on exploring the functional characteristics of the genome, along with the quick advancements in technology, positions functional genomics as a major force driving growth and innovation in the overall market.
Sequencing represents the leading market segment
Sequencing technology is the main component of the market due to its crucial role in deciphering the genetic information found in DNA and RNA, making it the largest technological segment. The critical insights provided by sequencing drive this prominence in personalized medicine, genetic research, and diagnostic applications by uncovering genetic variations and mutations. Furthermore, the rise of NGS technologies is changing this field by offering unparalleled speed, accuracy, and cost-efficiency compared to traditional techniques. NGS enables a detailed analysis of genomes, exomes, and transcriptomes, allowing for progress in comprehending complex diseases, evolutionary biology, and microbial genomics.
Pharmaceutical and biotechnology companies exhibit a clear dominance in the market
Pharmaceutical and biotechnology companies are playing a major role in the market, emphasizing their significance in driving drug development and personalized medicine forward. These areas apply genomic data to identify novel targets for drugs, understand the genetic origins of diseases, and develop tailored treatments using individuals' genetic data. For instance, Illumina Inc., a top company in DNA sequencing and array-based technologies worldwide, partnered with Nashville Biosciences, LLC, a prominent clinical and genomic data company that is a subsidiary of Vanderbilt University Medical Center (VUMC), to reveal the five original members of the Alliance for Genomic Discovery (AGD). The extended agreement aims to quicken the treatment development process by conducting thorough genomics research and establishing a high-quality clinical genomics database. AbbVie, Amgen, AstraZeneca, Bayer, and Merck will pool their resources to fund the sequencing of 250,000 samples and can use the data for developing drugs and improving therapies.
North America leads the market, accounting for the largest genomics market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for genomics.
North America holds the largest market share due to its advanced healthcare system, significant investment in research and development, and the presence of top pharmaceutical and biotechnology companies. Additionally, the region's advanced technology in genomics and bioinformatics, along with these factors, is fostering a favorable environment for the development and advancement of the genomics field. North America's strong position in the global market is supported by the close collaboration between academic and research institutions with the industry, leading to innovation and setting trends that impact global genomics practices and policies.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the genomics industry include
Major players in the industry are involved in various strategic activities to uphold and strengthen their market presence. These businesses are making significant investments in research and development to launch new genomic technologies, services, and solutions that cater to their customers' changing needs. Working together, forming partnerships, and making acquisitions are important strategies that enable them to enhance their technological capabilities, enter new markets, and gain new genomic applications and intellectual property. Additionally, these top companies are focusing on improving their bioinformatics systems to manage and analyze the large amounts of data generated from genomic sequencing. This enables full solutions that help translate genomic findings into progress in clinical and agricultural sectors.